OSE Immunotherapeutics SA (ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation December 10, 2025 12:00 PM EST

Company Participants

Fiona Olivier - Chief Corporate Affairs & Investor Relations Officer Marc Le Bozec - CEO & Director Thomas Gidoin - Chief Financial Officer

Presentation

Fiona Olivier Chief Corporate Affairs & Investor Relations Officer

Good evening, and welcome to the webcast of OSE Immunotherapeutics. This evening, we’re going to talk about the strategic plan that we announced yesterday. My name is Fiona Olivier. I’m Chief Corporate Affairs and Investor Relations Officer at OSE. And it’s my pleasure to have Marc Le Bozec, our CEO; and Thomas Gidoin, who is our CFO.

This discussion will be in French. There are a simultaneous translation into English. So feel free to choose the language you prefer. I’m going to start by asking a few questions to Marc and Thomas. And then we’ll answer your questions. You can see on your screen at the bottom left, a system to ask questions, and we’ll try to answer as many questions as possible. I’m going to start off with you, Marc. You are the CEO and have been so for only 2 months. First, you were elected to the Board of Directors at the shareholder meeting on the 30th of September. And then 10 days – 2 days later, you were appointed CEO. What have you been doing since then?

Marc Le Bozec CEO & Director

Well, since then, we conducted an audit, which is best practice, when you tied up in a company, and we did this in a group because I believe a lot in teamwork, I don’t believe in Providence. Now it’s a little tiring, but communication is repetition. So I say this every day. We had a scientific, so labor and financial order. And on the basis of that, we developed together a strategy, which meant going quite

Recommended For You